Elsevier

Journal of Infection

Volume 52, Issue 4, April 2006, Pages e107-e108
Journal of Infection

Case Report
Tenofovir-induced renal tubular dysfunction presenting with hypocalcaemia

https://doi.org/10.1016/j.jinf.2005.07.014Get rights and content

References (11)

There are more references available in the full text version of this article.

Cited by (13)

  • Chemico-physical investigation of tenofovir loaded polymeric nanoparticles

    2012, International Journal of Pharmaceutics
    Citation Excerpt :

    Due to of its favorable resistance profile and activity against nucleoside-resistant HIV-1 strains, PMPA has been widely applied in therapy (Wainberg et al., 1999; Shirasaka et al., 1995). Some instances of both PMPA and PMPA DF toxicities were reported (hypophosphatemia and decrease of tubular phosphate reabsorption in HIV-positive adults (Badiou et al., 2006), renal tubular dysfunction presenting with hypocalcaemia (Williams and Chadwick, 2006), acute renal failure, Fanconi syndrome in AIDS patients (Malik et al., 2005) and fatal lactic acidosis (Giola et al., 2005)). These toxicities could be ascribed to the nephrolithiasis and hydronephrosis that might occur in an HIV-infected man receiving PMPA (Cicconi et al., 2004).

  • Antiviral drugs

    2009, Side Effects of Drugs Annual
    Citation Excerpt :

    The authors suggested that multiple drug interactions with tenofovir can lead to an increased risk of acute tubular necrosis and that frequent monitoring of renal function is warranted in any patients who are taking these combinations. Tenofovir has been associated with acute renal failure and Fanconi's syndrome(63A,64A). The risk seems to be increased in patients who are taking tenofovir concurrently with ritonavir, lopinavir+ritonavir, didanosine, or atazanavir.

View all citing articles on Scopus
View full text